Danielle Campbell to Humans
This is a "connection" page, showing publications Danielle Campbell has written about Humans.
Connection Strength
0.349
-
A Community Call to Action to Prioritize Inclusion and Enrollment of Women in HIV Cure-related Research. J Acquir Immune Defic Syndr. 2022 12 15; 91(5):e12-e14.
Score: 0.092
-
"It comes altogether as one:" perceptions of analytical treatment interruptions and partner protections among racial, ethnic, sex and gender diverse HIV serodifferent couples in the United States. BMC Public Health. 2022 07 09; 22(1):1317.
Score: 0.091
-
SARS-CoV-2 Booster Vaccination for Participants in "HIV Cure"-Related Clinical Trials. J Acquir Immune Defic Syndr. 2022 03 01; 89(3):e30.
Score: 0.022
-
SARS-CoV-2 Vaccination in the Context of Ongoing HIV Cure-Related Research Studies. J Acquir Immune Defic Syndr. 2021 08 01; 87(4):e232-e233.
Score: 0.021
-
Ethics of HIV cure research: an unfinished agenda. BMC Med Ethics. 2021 06 30; 22(1):83.
Score: 0.021
-
Impact of dedicated women's outreach workers (WOWs) on recruitment of women in ACTG clinical studies. HIV Res Clin Pract. 2021 04; 22(2):37-45.
Score: 0.021
-
Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry. AIDS Res Hum Retroviruses. 2022 01; 38(1):50-63.
Score: 0.021
-
Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research. HIV Res Clin Pract. 2021 02; 22(1):14-30.
Score: 0.021
-
Reasons People Living with HIV Might Prefer Oral Daily Antiretroviral Therapy, Long-Acting Formulations, or Future HIV Remission Options. AIDS Res Hum Retroviruses. 2020 12; 36(12):1054-1058.
Score: 0.020
-
Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366. AIDS Res Hum Retroviruses. 2020 04; 36(4):268-282.
Score: 0.019